|
**Overview**: Bone Health Screen Panel**Introduction**: The Bone Health Screen Panel is a diagnostic tool designed to assess bone health using serum samples. In India, osteoporosis affects ~20-30 percent of postmenopausal women and elderly men, with vitamin D deficiency (70-90 percent), low calcium intake, and secondary hyperparathyroidism common due to malnutrition, low sun exposure, and urbanization. High morbidity from underdiagnosis in rural/low-SES groups, limited DEXA access, delayed supplements leading to fractures and disability. Per biochemistry practices aligned with ICMR and Endocrine Society of India guidelines, the test employs spectrophotometry for calcium, phosphorus, ALP, vitamin D, PTH over 1-2 days with high sensitivity/specificity, valuable for early detection of metabolic bone disease. This diagnostic falls under bone health screening and targets at-risk individuals (elderly, postmenopausal, low sun exposure), addressing accurate detection to guide vitamin D/calcium supplementation. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing fracture risk. Its serum-based approach ensures reliable detection.**Other Names**: Bone Health Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.**Historical Milestone**: Expanded for vitamin D screening; in India, prominence with deficiency epidemic.**Purpose**: The test assesses 5 parameters including calcium and vitamin D to guide bone health evaluation, detect deficiencies, inform supplementation.**Test Parameters**: 1. Calcium, 2. Phosphorus, 3. Alkaline Phosphatase, 4. Vitamin D, 5. PTH.**Pretest Condition**: Fasting 10-12 hours recommended; patients should report bone pain, fractures, or risk factors.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on bone pain, fractures, diet, sun exposure, family osteoporosis history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated bone disorders including fractures, benefits of early detection, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using spectrophotometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or recent meals can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate bone health risk, necessitating specialist input. Normal may require follow-up in high-risk individuals.**Specialist Consultation**: Endocrinologists or orthopedists should be consulted for management.**Additional Supporting Tests**: DEXA scan for confirmation.**Test Limitations**: May miss early osteoporosis; comprehensive approach required.**References**: Indian Journal of Endocrinology 2024, Bone Health Studies India 2023. |
